

Change Notice

Advanced Cardiovascular Life Support Provider Manual

Print ISBN 978-1-61669-400-5, AHA Product Number 15-1005

eBook ISBN 978-1-61669-404-3, AHA Product Number 15-3100

Print Page Number	Location	Original Text	Change	When Change Was Made
37	Part 4, in the section “Overview of the BLS Assessment,” in the paragraph after Figure 12, first sentence	minus right atrial relaxation	minus left ventricular relaxation	At next printing or update after 2/21/2017
95	Part 5, in the Cardiac Arrest: VF/Pulseless VT Case, in the section “Minimal Interruption of Chest Compressions,” third paragraph, second sentence	minus right atrial relaxation	minus left ventricular relaxation	At next printing or update after 2/21/2017
99	Part 5, in the Cardiac Arrest: VF/Pulseless VT Case, in the section “Shock and Vasopressors,” paragraph starting with “Epinephrine hydrochloride is used during resuscitation primarily for...”	β -adrenergic	α -adrenergic	At next printing or update after 2/21/2017
106	Part 5, in the Cardiac Arrest: VF/Pulseless VT Case, under “Antiarrhythmic Agents,” in the section “Amiodarone,” second bullet, second sentence	It also has β -adrenergic and β -adrenergic blocking properties.	It also has α -adrenergic and β -adrenergic blocking properties.	At next printing or update after 10/24/2016
131	In the section Rapid Recognition Is the Key to Management, last paragraph, third sentence	heart rate greater than 150/min	heart rate of 150/min or greater	At next printing or update after 12/21/2016